Telomir Pharmaceuticals, Inc. 8-K

What Happened

• On February 17, 2026, Telomir Pharmaceuticals, Inc. filed an 8-K announcing new preclinical in vitro data for its investigational compound Telomir‑1 (Telomir‑Zn) in human triple‑negative breast cancer (TNBC) cell lines. The company reported near‑complete tumor cell mortality in MDA‑MB‑468 at 72 hours and significant partial reductions in viable cells at 72 hours in HCC70 and MDA‑MB‑231. Addition of supplemental iron attenuated the compound’s tumor cell mortality, supporting an iron‑dependent mechanism consistent with prior metal‑modulating activity. Two additional TNBC lines (BT‑549 and HCC1806) are under evaluation. Telomir also referenced prior zebrafish xenograft studies showing statistically significant reductions in tumor growth and metastasis in select TNBC models.

Key Details

• Filing date: February 17, 2026 (8‑K reporting other events).
• Cell‑line results at 72 hours: near‑complete kill in MDA‑MB‑468; significant partial reductions in HCC70 and MDA‑MB‑231.
• Iron‑rescue: supplemental iron attenuated Telomir‑Zn–induced cell mortality, indicating an iron‑dependent mechanism.
• Development path: preparing a TNBC mouse xenograft study in a mammalian system, continuing IND‑enabling activities, and anticipates submitting an IND in Q1 2026; previously completed GLP safety/toxicology studies in rats and dogs showed no treatment‑related adverse toxicity.

Why It Matters

• For investors, these preclinical data provide evidence that Telomir‑1 has activity across multiple TNBC subtypes and a defined, iron‑dependent mechanism of action, which helps validate the company’s biological hypothesis beyond a single cell model. The company’s plan to advance mammalian xenograft studies, continued IND‑enabling work, and an anticipated IND submission in Q1 2026 are near‑term development milestones to monitor. Remember these are preclinical findings (in vitro and zebrafish); clinical safety and efficacy in humans remain to be demonstrated.